Rare Disease Drugs and India’s Emerging Pharmaceutical Opportunity

India’s Next Pharmaceutical Frontier

Rare Disease Drugs and India’s Emerging Pharmaceutical Opportunity: India has built a major global position in generic medicines by combining large-scale manufacturing with relatively affordable drug production. A similar opportunity is now emerging in the field of rare-disease medicines, where high prices and limited patient populations have traditionally restricted access.

Rare diseases affect relatively few people individually, but their combined impact is substantial. There are around 8,000 rare diseases worldwide, while 1,004 rare genetic disorders have been reported in India.

Because individual diseases have small patient populations, many medicines are classified as orphan drugs, reflecting the limited commercial incentive for pharmaceutical companies to develop them.

Lessons From the Orphan Drug Act

The United States Orphan Drug Act of 1983 introduced incentives to encourage companies to develop medicines for rare diseases. These included tax incentives, grants, regulatory fee waivers and market exclusivity.

The policy contributed to a significant increase in orphan-drug approvals in the United States. Japan, Australia and the European Union subsequently introduced comparable policy frameworks.

However, small patient populations can result in extremely high treatment prices. Some rare-disease therapies can cost $100,000 or more annually, creating major affordability challenges.

Static GK fact: The term orphan drug generally refers to a medicine developed specifically for a rare disease or condition for which conventional commercial incentives may be insufficient.

India’s Access Challenge

India provides financial assistance of up to ₹50 lakh per patient under its rare-disease support framework. However, this amount may not cover the full cost of certain advanced therapies.

Gene therapies and other specialised treatments can cost several crores, resulting in dependence on crowdfunding and charitable support. Government-supported crowdfunding platforms have listed thousands of children requiring treatment, while the aggregate estimated treatment requirement runs into thousands of crores.

Another major limitation is availability. Existing medicines address only a small proportion of rare diseases, leaving many patients without an approved treatment option.

Challenges in Developing Rare-Disease Drugs

Rare-disease drug development presents two fundamental research problems.

First, companies must identify enough patients to conduct meaningful clinical trials. Second, researchers need suitable endpoints to determine whether a treatment has produced a clinically relevant improvement.

Even after regulatory approval, manufacturing medicines economically at relatively small volumes and distributing them to geographically dispersed patients remain significant challenges.

India’s Research Advantage

India’s population of more than 1.4 billion provides a potentially large patient pool even for conditions with very low prevalence.

Certain communities also have higher prevalence of particular inherited disorders because of patterns of endogamy. Such population characteristics can help researchers identify patient cohorts and study disease-linked genetic variations.

India’s diverse population and diaspora also provide opportunities for research into genetic mutations, disease mechanisms and personalised therapies.

Static GK Tip: Endogamy refers to marriage within a defined social, ethnic or community group. In some populations, it can increase the frequency of particular inherited genetic conditions.

Linking Patients With Drug Development

Despite its potential, India has relatively limited participation in international orphan-drug clinical trials.

One proposed approach is to encourage partnerships between multinational pharmaceutical companies, Indian research institutions, hospitals and patient organisations. Such collaboration could establish dedicated rare-disease research and development centres within India.

A benefit-sharing approach could also link Indian participation in research with improved domestic access to the resulting medicines.

India’s Pharmaceutical Manufacturing Strength

India already has extensive capabilities in generic medicines, biosimilars and advanced therapies. Indian manufacturers supply a substantial share of generic medicines used internationally, while domestic facilities have also developed advanced treatments such as CAR-T cell therapy.

India’s regulatory framework provides another potential advantage. Under Rule 101 of the New Drugs and Clinical Trials Rules, 2019, certain drugs already approved in specified countries can qualify for regulatory pathways that may avoid repeating certain clinical requirements in India, subject to applicable conditions.

Greater clarity and transparency in regulatory guidance could make this pathway more predictable for manufacturers.

Policy Support for a Rare-Disease Hub

A targeted policy package could combine manufacturing incentives with guaranteed demand and research support.

Possible measures include tax incentives, production-linked incentives, technology-transfer programmes, Advance Market Commitments (AMCs) and support for exports to low- and middle-income countries.

Distribution could be strengthened through Centres of Excellence for Rare Diseases, Central Government Health Scheme facilities and Pradhan Mantri Bhartiya Janaushadhi Kendras, wherever appropriate.

The broader objective would be to reduce the initial risks of rare-disease drug development and manufacturing while creating a commercially sustainable ecosystem.

Static Usthadian Current Affairs Table

Rare Disease Drugs and India’s Emerging Pharmaceutical Opportunity: